GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » Earnings per Share (Diluted)

GMAB (Genmab AS) Earnings per Share (Diluted) : $1.74 (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab AS Earnings per Share (Diluted)?

Genmab AS's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $0.84. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $1.74.

Genmab AS's EPS (Basic) for the three months ended in Dec. 2024 was $0.84. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $1.75.

Genmab AS's EPS without NRI for the three months ended in Dec. 2024 was $0.63. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $1.51.

During the past 12 months, Genmab AS's average EPS without NRIGrowth Rate was 42.90% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 42.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 19.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 29.60% per year.

During the past 13 years, Genmab AS's highest 3-Year average EPS without NRI Growth Rate was 119.20% per year. The lowest was -13.30% per year. And the median was 20.60% per year.


Genmab AS Earnings per Share (Diluted) Historical Data

The historical data trend for Genmab AS's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Earnings per Share (Diluted) Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.18 0.68 1.18 0.97 1.70

Genmab AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.29 0.31 0.30 0.84

Competitive Comparison of Genmab AS's Earnings per Share (Diluted)

For the Biotechnology subindustry, Genmab AS's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's PE Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's PE Ratio falls into.


;
;

Genmab AS Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Genmab AS's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (A: Dec. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(1101.361-0)/646.329
=1.70

Genmab AS's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (Q: Dec. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(539.869-0)/641.539
=0.84

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Genmab AS  (NAS:GMAB) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Genmab AS Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Genmab AS's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Industry
Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.